CMS Eyeing Test To Lower Part B Drug Payments Through ASP Formula Change
This article was originally published in The Pink Sheet Daily
Agency looks to its innovation center in lieu of legislation to curb spending; new budget plans cites $7.8bn in 10-year savings from rates set at ASP+3%.
You may also be interested in...
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
Former CMS acting administrator Andy Slavitt says agency’s direction during Biden administration depends on nominee, but trust fund’s looming insolvency will be ‘an issue you can’t avoid.’ The president’s priorities around health equity, racial justice and mental health will make their way into CMS policy and demonstration models, Slavitt suggests.
Demonstration, which may not survive scrutiny from the Biden Administration, includes some protections, such as prohibiting Tennessee from excluding drugs described in the Medicare Part D protected classes policy.